BidaskClub downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a research note published on Tuesday morning, BidAskClub reports.

COLL has been the subject of a number of other reports. SunTrust Banks started coverage on shares of Zoetis in a report on Tuesday, March 19th. They set a hold rating and a $100.00 price objective for the company. HC Wainwright reaffirmed a buy rating on shares of Ballard Power Systems in a report on Friday, May 3rd. Janney Montgomery Scott started coverage on shares of PLx Pharma in a report on Friday, April 12th. They set a buy rating for the company. Cantor Fitzgerald set a $135.00 price objective on shares of Zimmer Biomet and gave the company a buy rating in a report on Friday, April 26th. Finally, ValuEngine lowered shares of Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $26.17.

Shares of COLL opened at $11.40 on Tuesday. The company has a quick ratio of 1.19, a current ratio of 1.24 and a debt-to-equity ratio of 0.22. Collegium Pharmaceutical has a 1 year low of $10.55 and a 1 year high of $21.20. The firm’s 50 day moving average is $12.14.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. Collegium Pharmaceutical had a negative net margin of 10.36% and a negative return on equity of 30.87%. The business had revenue of $74.52 million during the quarter, compared to analyst estimates of $70.10 million. Analysts forecast that Collegium Pharmaceutical will post -0.4 earnings per share for the current fiscal year.

In related news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $15.09, for a total value of $377,250.00. Following the completion of the transaction, the director now directly owns 207,170 shares of the company’s stock, valued at $3,126,195.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Joseph Ciaffoni sold 7,436 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $11.59, for a total transaction of $86,183.24. Following the completion of the transaction, the chief executive officer now directly owns 190,755 shares of the company’s stock, valued at $2,210,850.45. The disclosure for this sale can be found here. Over the last three months, insiders sold 91,144 shares of company stock valued at $1,171,256. 8.08% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Macquarie Group Ltd. lifted its position in Collegium Pharmaceutical by 8.7% in the fourth quarter. Macquarie Group Ltd. now owns 2,759,007 shares of the specialty pharmaceutical company’s stock worth $47,372,000 after buying an additional 221,779 shares during the last quarter. BlackRock Inc. lifted its position in Collegium Pharmaceutical by 8.7% in the fourth quarter. BlackRock Inc. now owns 2,619,718 shares of the specialty pharmaceutical company’s stock worth $44,980,000 after buying an additional 210,145 shares during the last quarter. Millennium Management LLC lifted its position in Collegium Pharmaceutical by 863.4% in the fourth quarter. Millennium Management LLC now owns 1,305,001 shares of the specialty pharmaceutical company’s stock worth $22,407,000 after buying an additional 1,169,537 shares during the last quarter. Rice Hall James & Associates LLC lifted its position in Collegium Pharmaceutical by 27.8% in the first quarter. Rice Hall James & Associates LLC now owns 1,191,141 shares of the specialty pharmaceutical company’s stock worth $18,034,000 after buying an additional 259,015 shares during the last quarter. Finally, Cortina Asset Management LLC lifted its position in Collegium Pharmaceutical by 81.0% in the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock worth $6,703,000 after buying an additional 228,035 shares during the last quarter. 94.15% of the stock is owned by hedge funds and other institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Read More: What is the Federal Reserve?

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.